Scientific Programme

PACS 2007
Thursday, October 25

**HALL A**

8.30 - 10.30  **Plenary session**

**THE IMPACT OF GLOBAL CARDIOVASCULAR RISK ON ACS PREVENTION AND TREATMENT**

*Chairpersons:* M. Scherillo (Benevento, Italy)
M. Uguccioni (Rome, Italy)

- ✔ Setting new targets in cholesterol control: Is lower better anyway?
  T.R. Pedersen (Oslo, Norway)

- ✔ Blood pressure control and atherosclerosis progression
  P. Verdecchia (Perugia, Italy)

- ✔ Is C-Reactive Protein really useful in improving risk stratification in CVD?
  L.M. Biasucci (Rome, Italy)

- ✔ Cardiovascular risk in metabolic syndrome
  S. Pede (S. Pietro Vernotico-BR, Italy)

- ✔ Secondary prevention: Adherence to evidence-based treatments in clinical practice
  F. Colivicchi (Rome, Italy)

10.30 - 11.00  **Visit of posters and exhibition**
Thursday, October 25

HALL A

11.00 - 13.00  Symposium

OPTIMAL ANTIPLATELET TREATMENT OF ACS-PCI PATIENTS

Chairpersons:  G.F. Gensini (Florence, Italy)
                V. Toschi (Milan, Italy)

✓ Platelet biology and receptors: What makes them stick?
  M. Cattaneo (Milan, Italy)

✓ Determinants of inter-individual variability in response to anti-platelet drugs
  P. Golino (Caserta, Italy)

✓ Acute and chronic needs: Which anti-platelet regimen and when?
  S. Savonitto (Milan, Italy)

✓ Potential developments in anti-platelet therapy for ACS-PCI
  S. De Servi (Legnano-MI, Italy)

HALL B

11.00 - 13.00  Symposium

ASYMPTOMATIC LEFT VENTRICULAR DYSFUNCTION:
PROBLEMS AND PERSPECTIVES FOR HEART FAILURE PREVENTION

Chairpersons:  F. Fedele (Rome, Italy)
                G. Speciale (Rome, Italy)

✓ Epidemiology and natural history of asymptomatic left ventricular dysfunction
  S. Urbinati (Bologna, Italy)

✓ Early cost-effective recognition of asymptomatic left ventricular dysfunction in high risk population
  G. Ansalone (Rome, Italy)

✓ Preventing the development of left ventricular dysfunction in hypertensive patients
  E. Agabiti Rosei (Brescia, Italy)

✓ Renin-angiotensin system blockade in the management of asymptomatic left ventricular dysfunction
  B. Trimarco (Naples, Italy)

✓ Additive beneficial effects of beta-blocker in the prevention of symptomatic heart failure
  A. Genovesi Ebert (Livorno, Italy)
Thursday, October 25

HALL B

13.00 - 14.30  Luncheon panel

THE ROLE OF GP IIb/IIIa INHIBITORS IN THE MANAGEMENT OF ACS: FROM PATHOPHYSIOLOGY TO CLINICAL OUTCOME

Chairpersons:  M. Lettino (Pavia, Italy)
               M. Tubaro (Rome, Italy)

✓ Are platelet inhibition, coronary flow and myocardial reperfusion important targets in ACS patients?
   L. Bolognese (Arezzo, Italy)

✓ Gp IIb/IIIa inhibitors in ACS
   C. Cavallini (Perugia, Italy)

HALL C

13.00 - 14.30  Luncheon panel

OPTIMAL STEMI TREATMENT

Chairpersons:  G. Casella (Bologna, Italy)
               F. Romeo (Rome, Italy)

✓ Myocardial infarction and pre-hospital selection. How can we improve patient outcome
   P. Goldstein (Lille, France)

✓ Quicker and wider use of thrombolytics: How to implement a reperfusion strategy for all suitable STEMI patients
   C. Fresco (Udine, Italy)

✓ STEMI network: Italian experiences
   M. Del Pinto (Perugia, Italy)

✓ Needle-catheter integration: Current status and future advances
   F. Weidinger (Vienna, Austria)

14.30 - 15.00  Visit of posters and exhibition
Thursday, October 25

15.00 - 17.00  **Symposium**

**ACS GUIDELINES, CLINICAL PRACTICE AND QUALITY OF CARE**

*Chairpersons:*  A. Gitt (Ludwigshafen, Germany)
Y. Hasin (Poriya, Israel)

- ✔ Pre-hospital thrombolysis therapy in France for acute myocardial infarction
  P. Goldstein (Lille, France)

- ✔ Hub-and-spoke hospital networks: A tiered system of care
  A. Gitt (Ludwigshafen, Germany)

- ✔ PCI for high risk patients in Europe
  Y. Hasin (Poriya, Israel)

- ✔ ICCU Registries: An Italian experience
  G. Steffenino (Cuneo, Italy)

- ✔ Accreditation of acute cardiac care as cardiological subspecialty
  M. Heras (Barcelona, Spain)

- ✔ New ESC NSTEACS guidelines
  A. Gaspardone (Rome, Italy)
Thursday, October 25

HALL B

15.00 - 17.00  Symposium

MANAGING THE HIGH RISK PATIENT WITH LEFT VENTRICULAR DYSFUNCTION AFTER ACUTE CORONARY SYNDROMES

Chairpersons:  C. Greco (Rome, Italy)
               P. Verdecchia (Rome, Italy)

✓ Clinical impact of left ventricular dysfunction after acute coronary syndromes
   C. Riccio (Caserta, Italy)

✓ Pharmacological options to limit left ventricular remodeling after ACS: The role of RAAS inhibition
   B. Trimarco (Naples, Italy)

✓ Safety and efficacy of ARBs after ACS
   M. Volpe (Rome, Italy)

✓ ACE-inhibitors, ARBs or both after ACS?
   A.P. Maggioni (Florence, Italy)

✓ Blood pressure control and CRP reduction: New insights in the effects of ARBs
   C. Ferri (L’Aquila, Italy)
Thursday, October 25

17.00 - 18.00  **Magistral Lecture**

**The use of biomarkers in acute coronary syndromes**
**Room for improvement?**

Allan S. Jaffe (Rochester, MN, USA)

Dr. Allan S. Jaffe is Professor of Medicine and Director of Cardiovascular Laboratory Medicine at the Mayo Clinic in Rochester, Minnesota.

He is a cardiologist by training who has a long and distinguished career in the care of patients with acute ischemic heart disease.

His research efforts have focused on the development and clinical testing of biomarkers related to myocardial injury, thrombosis and inflammation.

He has published widely and is a member of most of the most prestigious editorial boards in both Cardiology and Laboratory Medicine.

Chairperson: M. Santini (Rome, Italy)
Friday, October 26

8.30 - 10.30  **Plenary session**

**NEW FRONTIERS IN THE MANAGEMENT OF ACUTE HEART FAILURE**

*Chairpersons:*  
F. Fedele (Rome, Italy)  
M. Gheorghiade (Chicago, IL, USA)

- Epidemiology and pathophysiology of acute heart failure  
  L. Tavazzi (Pavia, Italy)

- Haemodynamic and biochemical monitoring of AHF  
  A. Mebazaa (Paris, France)

- Optimal medical therapy of patients with preserved/high blood pressure  
  M. Gheorghiade (Chicago, IL, USA)

- Optimal medical therapy of patients with low blood pressure/cardiogenic shock  
  F. Follath (Zurich, Switzerland)

- The role of IABP and ventricular assist devices in acute heart failure  
  L. Torracca (Milan, Italy)

10.30 - 11.00  **Visit of posters and exhibition**
Friday, October 26

11.00 - 13.00  Symposium

AMI NETWORKS: THE OPTIMAL REPERFUSION PATHWAY FOR ST ELEVATION MYOCARDIAL INFARCTION PATIENTS

Chairpersons:  F.-J. Neumann (Bad Krozingen, Germany)
               M. Tubaro (Rome, Italy)

✓ How to organise networking for invasive treatment of patients with STEMI
  K. Huber (Vienna, Austria)
✓ Optimal anti-thrombotic therapy in primary PCI for STEMI
  G. De Luca (Novara, Italy)
✓ New standard for STEMI reperfusion strategies: Learning from FINESSE and CARESS
  F.-J. Neumann (Bad Krozingen, Germany)
✓ STEMI treatment in the real world: Learning from RIKS-HIA and Euro-Transfer
  M. Janzon (Linköping, Sweden)
✓ Panel discussion: What do you miss to implement best treatment strategies for patients?

11.00 - 13.00  Symposium

OPTIMAL MEDICAL THERAPY AFTER AN ACUTE CORONARY SYNDROME IN THE “REAL WORLD”

Chairpersons:  A. Boccanelli (Rome, Italy)
               G. Di Pasquale (Bologna, Italy)

✓ Setting priorities: Which drugs are certainly necessary?
  P. Faggiano (Brescia, Italy)
✓ How much should we lower cholesterol?
  C. Rapezzi (Bologna, Italy)
✓ LDL cholesterol and atherosclerotic plaque: The lower the better?
  F. Prati (Rome, Italy)
✓ Blood pressure control: Are all drugs equal after ACS
  M. Volpe (Rome, Italy)
✓ Aggressive management of the diabetic patient
  G. Casella (Bologna, Italy)
✓ How can we improve adherence and avoid discontinuation of effective therapies?
  K.A. LaBresh (Waltham, MA, USA)
Friday, October 26

**HALL B**

13.00 - 14.30  **Luncheon lecture**

**ATRIAL FIBRILLATION IN CHF AND THE IMPACT OF RAAS-INHIBITION**

K. Swedberg (Göteborg, Sweden)

*Chairperson:* F. Colivicchi (Rome, Italy)

**HALL C**

13.00 - 14.30  **Luncheon panel**

**ADVANCES IN ANTITHROMBOTIC THERAPY IN ACS**

*Chairperson:* M. Tubaro (Rome, Italy)

- Expanding role of Gp IIb/IIIa inhibitors in ACS
  M. Galli (Livorno, Italy)

- Factor Xa inhibitors in ACS therapy
  M. Lettino (Pavia, Italy)

14.30 - 15.00  **Visit of posters and exhibition**
Friday, October 26

15.00 - 17.00  Symposium

DYSLIPIDEMIA AND ACUTE CORONARY SYNDROMES

Chairpersons:  E. Mannarino (Perugia, Italy)
               K.K. Ray (Cambridge, UK)

✓ Aggressive cholesterol lowering: Evidence from controlled trials
  K.K. Ray (Cambridge, UK)

✓ When and how should we start lipid lowering treatment in ACS patients?
  T.R. Pedersen (Oslo, Norway)

✓ Lipid lowering treatment in normocholesterolemic patients
  F. Bernini (Parma, Italy)

✓ New drugs to treat dyslipidemia
  C. Cortese (Rome, Italy)

✓ Risk factors modification and outcome in ACS
  G.F. Mureddu (Rome, Italy)

✓ Impact of lipid lowering therapy withdrawal and discontinuation after ACS
  F. Colivicchi (Rome, Italy)

15.00 - 17.00  Symposium

ANTIPLATELET THERAPY IN ARTERIAL THROMBOSIS

Chairpersons:  F. Andreotti (Rome, Italy)
               M. Chiariello (Naples, Italy)

✓ The global burden of atherothrombosis
  R. De Caterina (Chieti, Italy)

✓ Combined antiplatelet therapy in STEMI and NSTEMI
  K. Huber (Vienna, Austria)

✓ Antiplatelet therapy in PCI
  F. Crea (Rome, Italy)

✓ Stroke and peripheral artery disease: Role of antiplatelet therapy
  C. Cimminiello (Vimercate-MI, Italy)
Saturday, October 27

8.30 - 10.30  **Plenary session**

NEW CLASSIFICATION OF MYOCARDIAL INFARCTION.
THE KEY ROLE OF BIOMARKERS

*Chairpersons:*  J. Alpert (Tucson, AZ, USA)
                 M. Tubaro (Rome, Italy)

- Universal definition of myocardial infarction
  K. Thygesen (Aarhus, Denmark)

- Evaluation of biomarker imprecision at the MI decision limits
  M. Plebani (Padua, Italy)

- Diagnostic criteria for reinfarction and procedure related MI
  A.S. Jaffe (Rochester, MN, USA)

- Pitfalls when applying biomarkers for the diagnosis of MI
  M. Galvani (Forlì, Italy)

- Diagnostic biomarker strategy for myocardial infarction
  B. Lindahl (Uppsala, Sweden)

10.30 - 11.00  **Visit of posters and exhibition**
Saturday, October 27

**HALL A**

11.00 - 13.00  **Symposium**

**UPDATE IN ANTITHROMBOTIC THERAPY IN ACS**

*Chairpersons:*  
F. Andreotti (Rome, Italy)  
K. Huber (Vienna, Austria)

- ✓ Is enoxaparin the heparin of choice?  
  C.J.M. Vrints (Antwerp, Belgium)

- ✓ Are direct thrombin inhibitors better than heparins?  
  A. Shpektor (Moscow, Russia)

- ✓ Fondaparinux: A breakthrough in ACS  
  M. Lettino (Pavia, Italy)

- ✓ Gp IIb/IIIa inhibitors: Still a pivotal role in ACS?  
  L. Bolognese (Arezzo, Italy)

- ✓ What does the new NSTEACS guidelines teach us?  
  D. Ardissino (Parma, Italy)

**HALL B**

11.00 - 13.00  **Symposium**

**PCI IN ACUTE CORONARY SYNDROMES**

*Chairpersons:*  
Y. Hasin (Poriya, Israel)  
F. Tomai (Rome, Italy)

- ✓ PCI for ACS in the real world: Results from registries  
  F. Schiele (Besançon, France)

- ✓ DES in ACS: Indications and results  
  D. Ardissino (Parma, Italy)

- ✓ Strategies in ACS: When and how  
  F. Tomai (Rome, Italy)

- ✓ How to improve PCI results  
  G. Di Sciascio (Rome, Italy)
Saturday, October 27

13.00 - 14.00  **Young Investigators Award and Closing Remarks**

Chairpersons:  F. Colivicchi (Rome, Italy)
                M. Tubaro (Rome, Italy)

- Patency of the infarct-related coronary artery correlates with brachial artery flow-mediated dilation
  I. Urazovskaya, E. Vasilieva, D. Skrypnik, A. Shpektor (Moscow, Russia)

- Impact of different revascularization strategies on clinical outcome in patients with multivessel coronary disease undergoing primary angioplasty
  S. Rigattieri¹, G. Biondi Zoccai², C. Musto¹, P. Silvestri¹, C. Di Russo¹, G. Ferraiuolo¹, P. Loschiavo¹
  (¹Rome, ²Turin, Italy)

- Probucol abolishes membrane ruffling and restores cellular migration in macrophages foam cells
  S. Costa¹, E. Favari¹, I. Zanotti¹, A. Granata², N. Ronda¹, R. Gatti¹, F. Bernini¹
  (¹Parma, ²Milan, Italy)

- Very late thrombosis in acute myocardial infarction: drug eluting versus uncoated stents
  D. Capodanno, N. Garro, V. Cammalleri
  (Catania, Italy)
Poster display

1. **ASSOCIATION BETWEEN 4G/5G POLYMORPHISM OF PLASMINOGEN ACTIVATOR INHIBITOR 1 AND SUCCESS OF THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION**
Y. Teraz, E. Pavlikova, A. Balatskiy, A. Yurovsky, L. Samokhodskaya, V. Moiseyev
(Moscow, Russia)

2. **QUALITY PERFORMANCE MEASURES IN 401 CONSECUTIVE PATIENTS HOSPITALIZED WITH NSTEMI IN A DISTRICT GENERAL HOSPITAL**
L. Moretti, P. Grossi, G. Gregori, R. Marconi, V. Parato
(Ascoli Piceno, Italy)

3. **INVASIVE STRATEGY IN NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME: EARLY OR LATE INVASIVE?**
L. Mendes, F. Seixo, J. Ferreira*, J. Santos, on behalf of the Portuguese Registry of Acute Coronary Syndromes Investigators (Setúbal, 'Carnaxide, Portugal)

4. **THE IMPORTANCE OF HAEMOGLOBIN A1C AS AN INDEPENDENT PROGNOSTIC FACTOR IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION**
M. Kmet, A. Pernat*, I. Kranjec*, B. Rajer*
(Novo Mesto, 'Ljubljana, Slovenia)

5. **INFLAMMATION AS A POSSIBLE CAUSE OF ST-ELEVATION MYOCARDIAL INFARCTION WITH NORMAL CORONARY ANGIOGRAPHY**
M. Damjanovic, D. Djordjevic-Radojkovic, Z. Perisic, M. Tomasevic, S. Apostolovic, M. Pavlovic, G. Koracevic, R. Jankovic
(Nis, Serbia)

6. **TRANSRADIAL CORONARY ANGIOPLASTY IN ACUTE MYOCARDIAL INFARCTION. A SINGLE CENTRE EXPERIENCE**
G. Nobile, G. Casella, A. Rubboli, M. Pallotti, P. Pavesi, P. Sangiorgio, G. Di Pasquale
(Bologna, Italy)

7. **PRIMARY CORONARY INTERVENTION FOR CARDIOGENIC SHOCK AT A HOSPITAL WITH OFF-SITE CARDIAC SURGICAL FACILITIES**
G. Casella, G. Nobile, A. Rubboli, M. Pallotti, P. Pavesi, P. Sangiorgio, G. Di Pasquale
(Bologna, Italy)

8. **ELECTROCARDIOGRAPHICALLY INVISIBLE MYOCARDIUM ZONES (CONCEPTION AND NEW RESEARCH TREND)**
I. Serafinovich
(Grodno, Belarus)

9. **CAN THE CARDIOLOGIST USE IN ICCU THE NON INVASIVE VENTILATION IN ACUTE CARDIOGENIC PULMONARY EDEMA COMPLICATED BY RESPIRATORY EFFORT?**
M. Poli, P. Trambaiolo, M. De Luca, C. Imbesi, U. Lukic, S. Accogli, G. Ferraiuolo
(Rome, Italy)

10. **EASY: ADHERENCE TO THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) GUIDELINES IN SPECIALISED MEDICAL SETTINGS: OBSERVATIONAL STUDY**
C. Rapezzi, S. Fagnani*, T. Piliego*
(Bologna, 'Basiglio-MI, Italy)
11. CLINICAL VALUE OF LEAD AVR IN ACUTE CORONARY SYNDROMES WITH NON-ST SEGMENT ELEVATION
   P. Noussan, G. Boccuzzi, H. Gallinari, A. Andria, S. Colangelo, R. Garbo, A. Sala, P. Zanini, M. Minelli
   (Turin, Italy, Madrid, Spain)

12. USEFULNESS OF A NEW MINIATURIZED ECHOCARDIOGRAPHY IN CRITICALLY ILL PATIENTS:
    PRELIMINARY DATA
   P. Trambaiolo, M. Poli, M. De Luca, V. Lukic, C. Imbesi, S. Accogli, G. Ferraiuolo
   (Rome, Italy)

13. VALUE OF INITIAL ECG PARAMETERS IN PREDICTING EVOLVING HEART FAILURE
   V. Agladze, V. Chumburidze, M. Agladze, T. Kikalishvili
   (Tbilisi, Georgia)

14. CORRELATION BETWEEN ST SEGMENT DEPRESSION AND CORONARY ARTERY LESIONS IN PATIENTS
    WITH ACUTE CORONARY SYNDROME
   V. Agladze, M. Agladze
   (Tbilisi, Georgia)

15. EVALUATION OF THE REPERFUSION IN THE ACUTE MYOCARDIAL INFARCTION WITH ST ELEVATION
    UNDER FIBRINOLYTIC TREATMENT WITH TNK VERSUS R-TPA ELECTROCARDIOGRAPHIC AND
    ANGIOGRAPHIC ANALYSIS
   A. Altamirano Castillo, U. Juárez Herrera, H. González Pacheco, G. Vieyra Herrera, G. Rojas Velasco,
   R. Cué Carpio, A. Álvarez Sangabriel, F. Martínez Espinoza, C. Martínez Sanchez
   (Ignacio Chavez, Mexico)

16. PRE-HOSPITAL THROMBOLYSIS IN ALTA IRPINIA: WORK IN PROGRESS
   G. Bellizzii, G. Carbone, R. Landi, G. Bianchini, C. Dragonetti, P. Guarino, C. Lo Conte, G. Manganelli,
   V. Pellecchia, M. Sicignano, A. Santamaria, R. Citro, E. Bossone
   (Ariano Irpino-AV, Naples, Avellino, Vallo della Lucania-SA, Cava de' Tirreni-SA, Italy)

17. SAFETY OF DUAL ANTIPLATELET THERAPY (ASPIRIN AND CLOPIDOGREL), BESIDE THROMBOLYSIS
    AND ENOXAPARIN, IN THE PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
   D. Djordjevic Radiojkovic, S. Apostolovic, Z. Perisic, M. Tomasevic, M. Pavlovic, M. Damjanovic, R. Jankovic
   (Nis, Serbia)

18. FEATURES OF CORONARY ARTERIES LESIONS IN PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE
    CORONARY SYNDROME AGAINST A BACKGROUND OF THE METABOLIC SYNDROME
   T. Glebovskaya, N. Solovjova, N. Burova
   (St. Petersburg, Russia)

19. THE PROGNOSTIC IMPACT OF KIDNEY DYSFUNCTION IS RELATED TO HAEMOGLOBIN LEVELS
    IN PATIENTS WITH NON-ST ELEVATION ACUTE CORONARY SYNDROMES
   (Lisbon, Portugal)

20. PREVENTION ON MORTALITY AND SUDDEN CARDIAC DEATH IN PATIENTS WITH CARDIOVASCULAR
    DISEASES: EFFECT OF HIGHLY PURIFIED OMEGA - 3 FATTY ACID (OMACOR)
   K. Hristova, S. Milanov, I. Filibev, D. Petrov
   (Sofia, Bulgaria)
21. A RELATIVE COMPARISON IN BASELINE CHARACTERISTICS, MANAGEMENT PRACTICES, AND IN HOSPITAL OUTCOMES IN 1,430 PATIENTS WITH ACS IN OUR CORONARY CARE UNIT VS. GRACE REGISTRY
U. Juárez Herrera, A. Altamirano Castillo, H. González Pacheco, G. Vieyra Herrera, A. Arias Mendoza, A. Álvarez Sangabriel, F. Martínez Espinoza, C. Martínez Sanchez
(Ignacio Chavez, Mexico)

22. QUANTITATIVE ECG INDICES IN DIFFERENTIATION OF NECROSIS AND ISCHEMIA IN BASAL ANTERIOR AREA OF THE LEFT VENTRICLE AT PATIENTS WITH NON Q WAVE ANTERIOR MYOCARDIAL INFARCTION
D. Karnialiuk, I. Serafimovich
(Grodno, Belarus)

23. THE USEFULNESS OF TIMI RISK INDEX IN PREDICTING PROGNOSIS IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION TREATED WITH DIFFERENT REPERFUSION THERAPIES
L. Mendes, F. Seixo, J. Santos, on behalf of the Portuguese Registry of Acute Coronary Syndromes Investigators
(Setúbal, Portugal)

24. HIGH-DOSE BOLUS TIROFIBAN IN ST-ELEVATION ACUTE MI PATIENTS REQUIRING INTERHOSPITAL TRANSFER FOR PRIMARY ANGIoplasty
M. Negrini, R. Seregni, E. Piccaluga, P. Danna, M. Viecca, B. Brusoni
(Milan, Italy)

25. CARDIAC MAGNETIC FINDINGS IN MIOCARDIAL INFARCTION: GENDER SUBGROUP ANALYSIS AND LONG TERM FOLLOW-UP
M. Perazzolo Marra, L. Cacciavillani, F. Corbetti, N. Gasparetto, C. Silva, G. Tarantini, A. Ramondo, S. Iliceto
(Padua, Italy)

26. THE EFFICIENCY OF THROMBOLYTIC DRUGS FOR PRE-HOSPITAL USE IN INFARCTION ACUTE PHASE STEMI
O. Pomogalova, S. Lebedev, V. Nevzorova, V. Shumatov
(Vladivostok, Russia)

27. CRP, TNF-<ALPHA>, IL6, IL10, NO, AND LEPTINS VALUES IN PATIENTS WITH STEMI & METABOLIC SYNDROME
O. Pomogalova, V. Nevzorova
(Vladivostok, Russia)

28. PROGNOSTIC VALUE OF SOLUBLE ADHESION MOLECULES VCAM-1 AND ICAM-1 IN PATIENTS WITH ACUTE CORONARY SYNDROMES
A. Postadzyian, A. Tcontcheva, I. Kehayov, Z. Maslarska, B. Finkov
(Sofia, Bulgaria)

29. EASY STUDY: MULTIPLE DETERMINANTS OF THE GAP BETWEEN NATIONAL CHOLESTEROL EDUCATION PROGRAM GUIDELINES AND CLINICAL PRACTICE IN SECONDARY CARE
C. Rapezzi1, E. Biagini1, P. Bellis2, M. Cafiero2, M. Velussi3, A. Ceriello3, S. Fagnani2, T. Piliego3, C. Schweiger4
(1Bologna, 2Naples, 3Trieste, 4Udine, 5Basiglio-MI, 6Rho-MI, Italy)

30. FARMACOINVASIVE STRATEGY VS. PRIMARY ANGIOplasty IN PATIENTS WITH AN ACUTE CORONARY SYNDROME WITH ST ELEVATION AGED >= 75 YEARS
F. Seixo1, J. Ferreira Santos1, L. Mendes2
(1Setubal, 2Lisboa, Portugal)
31. THE ELECTROCARDIOGRAPHY VALUE FOR MYOCARDIUM CHANGES ESTIMATION AT PATIENTS WITH ANTERIOR ST ELEVATION MYOCARDIAL INFARCTION TREATED BY ANGIOPLASTY
I. Serafinovich, D. Karnialiuk
(Grodno, Belarus)

32. THE «HYPERTROPHY-RUPTURE» PHENOMENA AS A POSSIBLE NEW PATHOGENIC MECHANISM OF HEART RUPTURES AT PATIENTS WITH MYOCARDIAL INFARCTION
I. Serafinovich, A. Savicky, D. Karnialiuk
(Grodno, Belarus)

33. ACCURACY OF LOW DOSE DOBUTAMINE ECHOCARDIOGRAPHY IN DETECTION OF MYOCARDIAL VIABILITY OF MENOFIA UNIVERSITY
A. Serag
(Shebin El Kom, Egypt)

34. ARRHYTHMIAS IN PATIENTS WITH ACUTE CORONARY SYNDROME
O. Toman, M. Poloczek, J. Parenica, R. Jenysova, J. Spinar
(Brno, Czech Republic)

35. ACUTE MYOCARDITIS OR MYOCARDIAL INFARCTION WITH ANGIOGRAFICALLY NORMAL CORONARY ARTERIES (MINCA) IN YOUNG PATIENTS - CAN WE DIFFERENTIATE IT?
O. Toman, J. Parenica, M. Poloczek, P. Kala, R. Jenysova, J. Spinar
(Brno, Czech Republic)

36. DIAGNOSTIC AND PROGNOSTIC VALUE OF HEART FATTY-ACID BINDING PROTEIN IN FREQUENTLY OCCURRING CLINICAL SITUATIONS
I. Trifonov, A. Katrukha, O. Mazovets, A. Erlikh, A. Bereznikova, M. Medvedeva, N. Gratsiansky
(Moscow, Russia)